April 2022
Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/). The session, sponsored by INCATE and partners, was watched by potential investors and funders and included SMEs developing novel therapies through to vaccines and diagnostics.
![](https://www.amprologix.com/wp-content/uploads/2022/12/Picture-1.jpg)
Gordon presented our approach that aims to make antibiotic R&D profitable again. Currently, development costs for much needed antibiotics are prohibitive, far outweighing the income generated through sales. A range of innovative plans are now being trialled, including in the UK NHS to improve reimbursement and incentivise antibiotic R&D. However, our approach could bring new antibiotics to market for <$30m, making the returns (>$280m) very attractive.